Rituximab (anti-CD20)

目录号：A2009         批次号: A200911

打印

Rituximab (anti-CD20)是嵌合的anti-CD20单克隆抗体，与B细胞上的CD20抗原结合，结合亲和力为5 nM。MW: 143.86 KD。

抗体信息

CAS号 174722-31-7
配制 100 mM Pro-Ac, 20 mM Arg, pH 5.0
推荐同型对照 Human IgG1
来源 CHO cells
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
除菌 0.2 μM filtered
纯度 99%
蛋白浓度 19.96mg/ml
内毒素 ＜1EU/mg

Rituximab (anti-CD20)在文献中得到引用

The immune checkpoint LILRB4 promotes immune evasion and is correlated with disease progression and secondary malignancies in chronic lymphocytic leukemia [ Biomed Pharmacother, 2025, 189:118253] PubMed: 40516328
Distinct CD16a features on human NK cells observed by flow cytometry correlate with increased ADCC [ Sci Rep, 2024, 14(1):7938] PubMed: 38575779
TLR9 agonism differentially impacts human NK cell-mediated direct killing and antibody-dependent cell-mediated cytotoxicity [ Sci Rep, 2024, 14(1):14595] PubMed: 38918496
Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro [ Sci Rep, 2024, 14(1):28239] PubMed: 39548231
Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab [ Am J Nucl Med Mol Imaging, 2024, 14(1):31-40] PubMed: 38500749
Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab [ Am J Nucl Med Mol Imaging, 2024, 14(1):31-40] PubMed: 38500749
Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease [ Oncoimmunology, 2023, 12(1):2163784] PubMed: 36632565
Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease [ Oncoimmunology, 2023, 12(1):2163784] PubMed: 36632565
Development and implementation of natural killer cell simultaneous ADCC and direct killing assay [ Heliyon, 2023, 9(12):e22991] PubMed: 38125417
The role of the interaction between immunoglobulins in physiology and disease [ Ulm University Medical Center Institute of Immunology, 2023, ] PubMed: None

禁止用于人体及治疗！